Jayakrishna Ambati
29Patents
9h-index
8Co-inventors
68Inventor score
Filing activity: Dec 21, 2004 → Feb 12, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7816497B2 | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration | Physics | 45 | Active |
| US7553496B2 | VEGF-A as an inhibitor of angiogenesis and methods of using same | Human Necessities | 30 | Expired |
| US7928284B2 | Methods and animal model for analyzing age-related macular degeneration | Chemistry; Metallurgy | 26 | Active |
| US9453226B2 | Protection of cells from Alu-RNA-induced degeneration and inhibitors for protecting cells | Emerging Cross-Sectional Technologies | 18 | Active |
| US9707235B1 | Protection of cells from degeneration and treatment of geographic atrophy | Emerging Cross-Sectional Technologies | 16 | Active |
| US8008092B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | Physics | 15 | Active |
| US9198981B2 | Modulation of angiogenesis | Chemistry; Metallurgy | 15 | Active |
| US8846386B2 | sVEGFR-2 and its role in lymphangiogenesis modulation | Physics | 13 | Active |
| US8809517B2 | Method of inhibiting Alu RNA and therapeutic uses thereof | Physics | 9 | Active |
| US8778616B2 | Method of using CCR3 binding agents to detect choroidal neovascularization | Physics | 9 | Active |
| US9464289B2 | Methods of inhibiting Alu RNA and therapeutic uses thereof | Physics | 8 | Active |
| US9326983B2 | Compositions and methods for treating retinal degradation | Human Necessities | 7 | Active |
| US10300057B2 | Compositions and methods for treating retinal degradation | Human Necessities | 7 | Active |
| US11219623B2 | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis | Emerging Cross-Sectional Technologies | 5 | Active |
| US10864212B2 | Compositions and methods for treating retinal degradation | Human Necessities | 5 | Active |
| US10294220B2 | Compositions and methods for treating retinal degradation | Emerging Cross-Sectional Technologies | 4 | Active |
| US11602535B2 | Compositions and methods for treating retinal degradation | Human Necessities | 3 | Active |
| US8592482B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | Physics | 2 | Active |
| US8481508B2 | Ultra-small RNAs as toll-like receptor-3 antagonists | Chemistry; Metallurgy | 2 | Active |
| US11730743B2 | Protection of cells from degeneration and treatment of geographic atrophy | Emerging Cross-Sectional Technologies | 1 | Active |
| US11998547B2 | Compositions and methods for treating multiple sclerosis | Emerging Cross-Sectional Technologies | 1 | Active |
| US11717520B2 | Compositions and methods for treating retinal degradation | Emerging Cross-Sectional Technologies | 1 | Active |
| US12097201B2 | Compositions and methods for treating retinal degradation | Emerging Cross-Sectional Technologies | 0 | Active |
| US8957035B2 | Toll like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration | Human Necessities | 0 | Active |
| US11345756B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.